ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that it has completed enrollment of patients in a pivotal phase III clinical trial using pravastatin and fenofibrate to treat mixed dyslipidemia. Mixed dyslipidemia is the presence of elevated levels of “bad” cholesterol, low-density lipoproteins (LDL) and triglycerides and low levels of “good” cholesterol, high-density lipoproteins (HDL) in the blood.
The phase III clinical trial is being conducted at approximately 75 sites in the United States. This study compares the combination of pravastatin and fenofibrate to pravastatin alone and fenofibrate alone.
